Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD

Yang Ying; Chen Shuang; Zhang Zhen-Ying

doi:10.1002/iid3.574

Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD

Immun Inflamm Dis. 2022 Mar;10(3):e574. doi: 10.1002/iid3.574. Epub 2021 Dec 24.

Authors

Yang Ying¹, Chen Shuang², Zhang Zhen-Ying¹

Affiliations

¹ Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China.
² Department of Pathology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China.

Abstract

The management of acquired reactive perforating collagenosis (ARPC) is challenging. Here, we shared two cases of ARPC combined with elderly atopic dermatitis (AD) that did not respond well to conventional treatment but responded well to the monotherapy of dupilumab, which suggests that dupilumab may be an alternative option for the treatment.

Keywords: acquired reactive perforating collagenosis; atopic dermatitis; dupilumab.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antibodies, Monoclonal, Humanized / therapeutic use
Collagen Diseases* / complications
Collagen Diseases* / drug therapy
Dermatitis, Atopic* / complications
Dermatitis, Atopic* / drug therapy
Humans
Skin Diseases*

Substances

Antibodies, Monoclonal, Humanized
dupilumab